These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1689887)

  • 1. The effects of FK 506 on renal function after liver transplantation.
    McCauley J; Fung J; Jain A; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):17-20. PubMed ID: 1689887
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
    Fung JJ; Todo S; Jain A; McCauley J; Alessiani M; Scotti C; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):6-12. PubMed ID: 1689901
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of FK 506 and CyA on the Lewis rat renal ischemia model.
    Nalesnik MA; Lai HS; Murase N; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):87-9. PubMed ID: 1689911
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathologic observations in human allograft recipients treated with FK 506.
    Demetris AJ; Fung JJ; Todo S; Banner B; Zerbe T; Sysyn G; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):25-34. PubMed ID: 1689891
    [No Abstract]   [Full Text] [Related]  

  • 5. Interspecies comparison of the immunosuppressive efficacy and safety of FK 506.
    Thomson AW
    Transplant Proc; 1990 Feb; 22(1):100-5. PubMed ID: 1689883
    [No Abstract]   [Full Text] [Related]  

  • 6. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
    Li PK; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(3):123-55. PubMed ID: 1703724
    [No Abstract]   [Full Text] [Related]  

  • 7. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FK 506--an investigational immunosuppressant.
    Med Lett Drugs Ther; 1991 Oct; 33(854):94. PubMed ID: 1716722
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of cyclosporin A on the situ inflammatory response of human renal allograft rejection. A preliminary report.
    Häyry P; Ahonen J; von Willebrand E; Eklund B; Höckekstedt K; Kauste A; Taskinen E; Lautenschlager I; Lalla M; Sarelin H
    Scand J Immunol; 1982 Aug; 16(2):135-49. PubMed ID: 6753125
    [No Abstract]   [Full Text] [Related]  

  • 10. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
    Fung JJ; Todo S; Tzakis A; Demetris A; Jain A; Abu-Elmaged K; Alessiani M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):14-21. PubMed ID: 1703682
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450.
    Yoshimura R; Yoshimura N; Kusunose E; Hamashima T; Ohsaka Y; Kusunose M; Oka T; Kishimoto T; Maekawa M
    Transplant Proc; 1991 Feb; 23(1 Pt 1):311-3. PubMed ID: 1703686
    [No Abstract]   [Full Text] [Related]  

  • 12. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.
    Van Thiel DH; Iqbal M; Jain A; Fung J; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):37-40. PubMed ID: 1689893
    [No Abstract]   [Full Text] [Related]  

  • 13. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine.
    Demetris AJ; Banner B; Fung J; Shapiro R; Jordan M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):944-6. PubMed ID: 1703360
    [No Abstract]   [Full Text] [Related]  

  • 14. [Indications for liver transplantation in adults].
    Naouri A; Tissot E
    J Chir (Paris); 1990; 127(6-7):334-40. PubMed ID: 1698800
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative efficacy of immunosuppressive drugs in xenografting.
    Thomas FT; DeMasi RJ; Araneda D; Marchman W; Alqaisi M; Larkin EW; Condie RM; Carobbi A; Thomas JM
    Transplant Proc; 1990 Jun; 22(3):1083-5. PubMed ID: 1693452
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclosporine-associated nephrotoxicity is not intractable.
    Loertscher R
    Transplant Proc; 1987 Aug; 19(4):3486-9. PubMed ID: 3303520
    [No Abstract]   [Full Text] [Related]  

  • 17. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates.
    Monden M; Gotoh M; Kanai T; Valdivia LA; Umeshita K; Endoh W; Nakano Y; Kawai M; Ohzato H; Ukei T
    Transplant Proc; 1990 Feb; 22(1):66-71. PubMed ID: 1689904
    [No Abstract]   [Full Text] [Related]  

  • 18. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation.
    Kang Y; Mazer MA; DeWolf AM; Fung JJ; Gasior T; Venkataramanan R; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):21-2. PubMed ID: 1689889
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase.
    Vincent SH; Wang RW; Karanam BV; Klimko M; Alvaro R; Chiu SH
    Biochem Pharmacol; 1991 May; 41(9):1325-30. PubMed ID: 1708254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.